| GTO ID | GTC1573 |
| Trial ID |
NCT02631044
|
| Disease |
Follicular Lymphoma
|
Non-Hodgkin's Lymphoma
|
Mantle Cell Lymphoma
|
Diffuse Large B-Cell Lymphoma
|
Primary Mediastinal B-Cell Lymphoma
|
| Altered gene | CD19 |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | Breyanzi|Lisocabtagene maraleucel|liso-cel|JCAR017 |
| Location approved | US, Japan, EU, Switzerland, UK, Canada |
| Generation | 2nd |
| Phase | Phase1 |
| Recruitment status | Active, Not Recruiting |
| Title | Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (TRANSCEND-NHL-001) |
| Year | 2015 |
| Country | United States |
| Company sponsor | Juno Therapeutics, a Subsidiary of Celgene |
| Other ID(s) | 17001 |